Such findings also justify why early treatment with specific pharmacotherapy such as Ang II antagonism can potentially pan effects that not only induce BP reduction in CKD, but could limit pathological changes in arteries and improve the CV health beyond BP control; results of which may not be fully seen with other pharmacological interventions (Jeewandara et al., 2015; Quek et al., 2020). Here, AGT is linked to chronic kidney disease.